The acquisition expands BD's presence into the emerging affordable personal flow cytometer space, and helps expand the use of flow cytometry technology by researchers in regions of the world where ease of use and affordability are critical.
"The acquisition of Accuri Cytometers complements and broadens BD's offerings for life scientists by making flow cytometry more accessible to a wider audience of scientists and clinicians," said William Rhodes, President, BD Biosciences. "This includes researchers in scientific disciplines that have not traditionally used flow cytometry, such as environmental sciences, microbiology and marine biology."
The financial impact of the acquisition on fiscal year 2011 earnings has been incorporated into the guidance BD provided during its earnings call on February 8, 2011.
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
Colleen T. White, Corporate Communications – 201-847-5369
Zachary A. Nagle, Investor Relations – 201-847-5453